Skip to main content

Table 1 Baseline characteristics

From: Type 2 diabetes compromises the value of non-invasively measured augmentation index in predicting the severity of coronary artery disease: a hospital-based observational study

  Total
(n = 197)
Non-diabetic
(n = 113)
Diabetic
(n = 84)
p-value
Age(years) 59.2 ± 11.1 57.9 ± 11.0 60.9 ± 11.0 0.069
Gender(male), n(%) 142(72.1) 82(72.6) 59(70.2) 0.646
Hypertension, n(%) 128(65) 67(59.3) 61(72.6) 0.063
Hyperlipidemia, n(%) 45(22.8) 21(18.6) 24(28.6) 0.106
Current smokers, n(%) 101(51.3) 59(52.2) 41(48.8) 0.592
BMI(kg/m2) 25.2 ± 5.3 25.4 ± 4.9 25.1 ± 5.7 0.684
SYNTAX 16.4 ± 12.2 16.0 ± 11.9 17.0 ± 12.6 0.546
SYNTAX > 22, n(%) 60(30.5) 35(31.3) 25(29.8) 0.823
Lab data
 HbA1c(%) 6.4 ± 1.2 5.7 ± 0.4 7.3 ± 1.3 <0.3*
 Triglyceride(mmol/l) 1.8 ± 1.6 1.6 ± 0.8 2.0 ± 1.8 0.073
 LDL cholesterol(mmol/l) 2.6 ± 1.0 2.6 ± 1.0 2.5 ± 1.0 0.775
 HDL cholesterol(mmol/l) 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.045*
 Creatinine(μmol/l) 79.0 ± 17.6 77.8 ± 17.5 80.6 ± 17.7 0.260*
Medications
 ACEI, n(%) 21(10.7) 11(9.7) 10(11.9) 0.641
 ARB, n(%) 17(8.6) 6(5.3) 11(13.1) 0.057
 β-blockers, n(%) 35(17.8) 21(18.6) 14(16.7) 0.706
 Calcium channel blockers, n(%) 44(22.3) 14(12.4) 30(35.7) <0.3*
 Statins, n(%) 32(16.2) 10(8.8) 22(26.2) 0.9*
  1. *p value for comparison between the non-diabetic and diabetic groups; p < 0.05 indicates statistical significance. BMI body mass index, LDL low-density lipoprotein, HDL high-density lipoprotein, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker